Johnson & Johnson Says Crucell N.V. Bid Still Valid

October 29, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

AMSTERDAM, Oct 29 (Reuters) - U.S. healthcare group Johnson & Johnson (JNJ.N) said on Friday it stood by its bid for Crucell (CRCL.AS)(CRXL.O) after the Dutch biotechnology firm halted shipments of two vaccines pending an investigation.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions Europe

Johnson & Johnson Family of Companies